

Harmaline

Catalog No: tcsc0030704



Available Sizes

Size: 100mg



Specifications

CAS No:

304-21-2

Formula:

$C_{13}H_{14}N_2O$

Pathway:

Neuronal Signaling

Target:

Monoamine Oxidase

Purity / Grade:

>98%

Solubility:

DMSO (Need Ultrasonic and Warming)

Alternative Names:

Harmidine

Observed Molecular Weight:

214.26


Product Description

Harmaline is a potent and reversible **monoamine oxidase** inhibitor *in vivo*. Harmaline is a central nervous system stimulant and can be used to induce tremor in rodents.

IC50 & Target: Target: Monoamine oxidase^[1]

In Vitro:

Harmaline inhibits monoamine oxidases, thus increasing the levels of monoamine neurotransmitters (e.g., at 7-70 $\mu\text{M/kg}$ in rats)^[1]. Harmaline-induced tremor in rodents is a model of essential tremor. The tremor activity is dependent on harmaline dose. The first-line clinical essential tremor treatments propranolol, primidone and gabapentin and γ -hydroxybutyrate (GHB) significantly attenuate harmaline-induced tremor. The anticonvulsants valproate and carbamazepine and the mood stabilizer lithium suppress harmaline-induced tremor. The γ -amino-butyric acid (GABA) receptor subtype A receptor agonist muscimol attenuate harmaline-induced tremor. Harmaline (30 mg/kg) induces tremor in mice through the N-methyl-D-aspartate (NMDA) receptor, both competitive and non-competitive NMDA receptor antagonists, and AMPA receptor blockade, decreased harmaline-induced tremor^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!